Core Viewpoint - Rosen Law Firm is encouraging investors of James Hardie Industries plc to secure legal counsel before the December 23, 2025 deadline for a securities class action lawsuit related to misleading statements about the company's performance during a specific period [2][4]. Group 1: Class Action Details - The class action pertains to investors who purchased James Hardie common stock between May 20, 2025, and August 18, 2025, and may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A lawsuit claims that James Hardie misled investors regarding the strength of its North America Fiber Cement segment, falsely asserting that demand was strong while distributors were actually destocking inventory [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - Rosen Law Firm is reminding investors of Inspire Medical Systems, Inc. to secure counsel before the January 5, 2026 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 5, 2026 [3][5]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of CarMax, Inc. to secure legal counsel before the January 2, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from June 20, 2025, to November 5, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased CarMax securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 2, 2026 [3][6]. - The lawsuit alleges that CarMax's defendants made materially false statements regarding the company's growth prospects, which were overstated due to temporary market conditions [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - The founding partner of Rosen Law Firm was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Stride, Inc. for the period between October 22, 2024, and October 28, 2025, due to alleged misleading statements and omissions regarding the company's products and services [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Stride, Inc. made misleading statements about its products and services aimed at public and private schools, which included inflated enrollment numbers and non-compliance with statutory requirements [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Stride, Inc. securities during the Class Period [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by January 12, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is urging investors of Cytokinetics, Inc. to take action before the November 17, 2025 deadline related to a securities class action lawsuit concerning misleading statements about the company's New Drug Application for aficamten [2][6]. Group 1: Class Action Details - The class action pertains to investors who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025, and may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [4][6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of significant settlements, including over $438 million secured for investors in 2019, and has been recognized for its success in securities class action settlements [5]. Group 3: Case Allegations - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [6]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to investor damages when the true information was revealed [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hormel Foods Corporation due to allegations of materially misleading business information issued by the company [1]. Summary by Sections Investigation Announcement - Rosen Law Firm has announced an investigation into Hormel Foods Corporation for potential securities claims related to misleading business information [1]. Class Action Information - Shareholders who purchased Hormel securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. Recent Company Developments - On October 29, 2025, Hormel Foods cut its earnings forecast, citing price pressures, bird flu, and a fire at its Arkansas peanut butter production facility as contributing factors. The company also announced the departure of its CFO, leading to a 9.1% drop in stock price on the same day [3]. Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions. The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued to the public [1] Group 1: Legal Action and Investor Rights - Investors who purchased Zions Bancorporation securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Financial Impact and Company Disclosure - On October 15, 2025, Zions Bancorporation announced a $50 million charge-off related to a loan from its subsidiary, California Bank & Trust, due to misrepresentations and contractual defaults [3] - Following this announcement, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [5] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Legal Action - Shareholders of Firefly Aerospace who purchased securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Financial Performance - Firefly Aerospace reported a wider loss and lower revenue in its latest quarter, marking its first earnings report since its stock market debut [3]. - Following the negative earnings report, Firefly's stock fell by 15.3% on September 23, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar in 2020 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Marex Group plc during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between May 16, 2024, and August 5, 2025, and investors may be entitled to compensation through a contingency fee arrangement [1]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [4]. - As a result of these actions, Marex's financial statements were deemed unreliable, leading to misleading positive statements about its business and operations [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of aTyr Pharma, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit claims that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5]. Group 3: Next Steps for Investors - To join the class action, investors can visit the provided link or contact the law firm directly for more information [4][7]. - It is noted that no class has been certified yet, and investors are not represented unless they retain counsel [8].